These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

608 related items for PubMed ID: 12186805

  • 1. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase.
    Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, Tsuji H, Reaven GM, Cooke JP.
    Circulation; 2002 Aug 20; 106(8):987-92. PubMed ID: 12186805
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Ex vivo gene transferring of human dimethylarginine dimethylaminohydrolase-2 improved endothelial dysfunction in diabetic rat aortas and high glucose-treated endothelial cells.
    Lu CW, Guo Z, Feng M, Wu ZZ, He ZM, Xiong Y.
    Atherosclerosis; 2010 Mar 20; 209(1):66-73. PubMed ID: 19775692
    [Abstract] [Full Text] [Related]

  • 7. PRMT-1 and DDAHs-induced ADMA upregulation is involved in ROS- and RAS-mediated diabetic retinopathy.
    Chen Y, Xu X, Sheng M, Zhang X, Gu Q, Zheng Z.
    Exp Eye Res; 2009 Dec 20; 89(6):1028-34. PubMed ID: 19748504
    [Abstract] [Full Text] [Related]

  • 8. Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis.
    Weis M, Kledal TN, Lin KY, Panchal SN, Gao SZ, Valantine HA, Mocarski ES, Cooke JP.
    Circulation; 2004 Feb 03; 109(4):500-5. PubMed ID: 14732750
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Overexpression of dimethylarginine dimethylaminohydrolase inhibits asymmetric dimethylarginine-induced endothelial dysfunction in the cerebral circulation.
    Dayoub H, Rodionov RN, Lynch C, Cooke JP, Arning E, Bottiglieri T, Lentz SR, Faraci FM.
    Stroke; 2008 Jan 03; 39(1):180-4. PubMed ID: 18063827
    [Abstract] [Full Text] [Related]

  • 11. Involvement of DDAH/ADMA/NOS pathway in nicotine-induced endothelial dysfunction.
    Jiang DJ, Jia SJ, Yan J, Zhou Z, Yuan Q, Li YJ.
    Biochem Biophys Res Commun; 2006 Oct 20; 349(2):683-93. PubMed ID: 16959216
    [Abstract] [Full Text] [Related]

  • 12. Contribution of endogenous inhibitor of nitric oxide synthase to hepatic mitochondrial dysfunction in streptozotocin-induced diabetic rats.
    Chen N, Leng YP, Xu WJ, Luo JD, Chen MS, Xiong Y.
    Cell Physiol Biochem; 2011 Oct 20; 27(3-4):341-52. PubMed ID: 21471723
    [Abstract] [Full Text] [Related]

  • 13. Erythropoietin increases asymmetric dimethylarginine in endothelial cells: role of dimethylarginine dimethylaminohydrolase.
    Scalera F, Kielstein JT, Martens-Lobenhoffer J, Postel SC, Täger M, Bode-Böger SM.
    J Am Soc Nephrol; 2005 Apr 20; 16(4):892-8. PubMed ID: 15728783
    [Abstract] [Full Text] [Related]

  • 14. Taurine protects against low-density lipoprotein-induced endothelial dysfunction by the DDAH/ADMA pathway.
    Tan B, Jiang DJ, Huang H, Jia SJ, Jiang JL, Hu CP, Li YJ.
    Vascul Pharmacol; 2007 May 20; 46(5):338-45. PubMed ID: 17293168
    [Abstract] [Full Text] [Related]

  • 15. Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications.
    Yamagishi S, Ueda S, Nakamura K, Matsui T, Okuda S.
    Curr Pharm Des; 2008 May 20; 14(25):2613-8. PubMed ID: 18991678
    [Abstract] [Full Text] [Related]

  • 16. Enhancing kidney DDAH-1 expression by adenovirus delivery reduces ADMA and ameliorates diabetic nephropathy.
    Wetzel MD, Gao T, Stanley K, Cooper TK, Morris SM, Awad AS.
    Am J Physiol Renal Physiol; 2020 Feb 01; 318(2):F509-F517. PubMed ID: 31904280
    [Abstract] [Full Text] [Related]

  • 17. Inhibitory effect of resveratrol derivative BTM-0512 on high glucose-induced cell senescence involves dimethylaminohydrolase/asymmetric dimethylarginine pathway.
    Yuan Q, Peng J, Liu SY, Wang CJ, Xiang DX, Xiong XM, Hu CP, Li YJ.
    Clin Exp Pharmacol Physiol; 2010 May 01; 37(5-6):630-5. PubMed ID: 20132235
    [Abstract] [Full Text] [Related]

  • 18. Relationship between protective effects of rosiglitazone on endothelium and endogenous nitric oxide synthase inhibitor in streptozotocin-induced diabetic rats and cultured endothelial cells.
    Wang S, Jiang JL, Hu CP, Zhang XJ, Yang DL, Li YJ.
    Diabetes Metab Res Rev; 2007 Feb 01; 23(2):157-64. PubMed ID: 16770837
    [Abstract] [Full Text] [Related]

  • 19. GC-MS assay for hepatic DDAH activity in diabetic and non-diabetic rats by measuring dimethylamine (DMA) formed from asymmetric dimethylarginine (ADMA): evaluation of the importance of S-nitrosothiols as inhibitors of DDAH activity in vitro and in vivo in humans.
    Chobanyan K, Thum T, Suchy MT, Zhu B, Mitschke A, Gutzki FM, Beckmann B, Stichtenoth DO, Tsikas D.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Oct 15; 858(1-2):32-41. PubMed ID: 17825631
    [Abstract] [Full Text] [Related]

  • 20. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes.
    Yamagishi S, Ueda S, Okuda S.
    Med Hypotheses; 2007 Oct 15; 69(4):922-4. PubMed ID: 17368960
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.